Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents mixed signals: financial performance is stable, with improved earnings and cash distribution, but high leverage and sector weakness pose risks. The Q&A reveals no major disruption in multifamily capital markets and unique positioning in Alewife, but management's unclear response about income details raises concerns. The share buyback at a discount is positive, but overall market uncertainty and high debt levels temper optimism. The stock price is likely to remain stable over the next two weeks.
Net Income $0.42 per diluted share for Q1 2026, compared to $0.70 for Q1 2025. The decrease was driven by small mark-to-market declines on preferred stock and warrants, as well as a decrease in the change in net assets related to consolidated CMBS VIEs.
Earnings Available for Distribution $0.43 per diluted share in Q1 2026, compared to $0.41 per diluted share in Q1 2025. The increase was due to improved earnings performance.
Cash Available for Distribution $0.58 per diluted share in Q1 2026, compared to $0.45 per diluted share in Q1 2025. The increase was attributed to better cash flow performance.
Dividend Paid $0.50 per share in Q1 2026, which was 1.16x covered by cash available for distribution.
Book Value per Share Decreased slightly by 0.3% from Q4 2025 to $18.96 per diluted share, primarily driven by unrealized losses on preferred stock investments and stock warrants.
New Investments Over $30 million funded on 2 loans during Q1 2026, both paying a monthly coupon in the mid-teens.
Refinancing of Senior Unsecured Notes $180 million of senior unsecured notes maturing on May 1 were refinanced with a $242 million total return swap facility priced at SOFR plus 375 basis points with a 3-year term and 1-year extension option. This removed near-term liability, aligned floating rate structure with asset base, and provided $45 million of incremental capacity for deployment.
Re-REMIC Execution Generated $0.46 per share of book value appreciation, reduced repo financing by $75 million, and is expected to drive approximately $0.34 per share of annual CAD accretion going forward.
Portfolio Composition 90 investments with a total outstanding balance of $1.1 billion, allocated across sectors: 39.4% multifamily, 35.9% life sciences, 17.1% single-family rental, 3.9% storage, 1.6% marina, and 2.1% industrial.
Debt Outstanding $665.2 million with a weighted average cost of 5.2% and a weighted average maturity of 0.8 years.
AI Deployment: NREF is deploying AI across underwriting, portfolio monitoring, credit risk, and operations functions. This includes AI-assisted deal screening, predictive credit models, and generative AI for reporting and research.
Residential Market Positioning: NREF has 56% exposure to residential assets (SFR and multifamily). The multifamily market is in a supply trough, with deliveries expected to decline significantly in 2026 and 2027. Leasing data supports a positive outlook for residential operators.
Life Sciences Market Positioning: NREF's Alewife project is 71% leased, with strong demand from AI and life science companies. The project is strategically located near MIT and Cambridge, targeting high-quality tenants.
Refinancing of Senior Unsecured Notes: NREF refinanced $180 million of senior unsecured notes with a $242 million total return swap facility, improving balance sheet flexibility and reducing near-term liabilities.
Capital Recycling: Executed a re-REMIC transaction, generating $0.46 per share of book value appreciation and reducing repo financing by $75 million.
AI Integration Strategy: NREF is integrating AI to enhance underwriting, risk management, and operational efficiency, aiming for full optimization by 2027.
Net Income Decline: Net income per diluted share decreased from $0.70 in Q1 2025 to $0.42 in Q1 2026, driven by mark-to-market declines on preferred stock and warrants, as well as a decrease in net assets related to consolidated CMBS VIEs.
Book Value Decline: Book value per share decreased by 0.3% from Q4 2025 to $18.96 per diluted share, primarily due to unrealized losses on preferred stock investments and stock warrants.
Debt Maturity and Refinancing Risk: The company had to refinance $180 million of senior unsecured notes maturing on May 1, replacing them with a $242 million total return swap facility. While this removes near-term liability, it introduces floating rate exposure and dependency on market conditions for future refinancing.
Life Sciences Sector Risk: The life sciences sector has attracted scrutiny, and while the company highlights strong leasing momentum, the sector's overall volatility and dependency on AI-driven demand could pose risks.
Self-Storage Sector Weakness: The self-storage sector is in a cyclical bottoming process, with flat revenue expectations and NOI declines of 50 to 150 basis points for the year, which could impact returns.
High Leverage in Portfolio: The company has $665.2 million of debt outstanding with a weighted average cost of 5.2% and a weighted average maturity of 0.8 years, indicating high leverage and short-term refinancing needs.
Economic and Market Uncertainty: The macroeconomic environment remains 'noisy,' which could impact the company's ability to execute its investment and refinancing strategies effectively.
Second Quarter 2026 Guidance: Earnings available for distribution projected at $0.43 per diluted share at the midpoint, with a range of $0.38 to $0.48. Cash available for distribution projected at $0.54 per diluted share at the midpoint, with a range of $0.49 to $0.59.
Residential Market Outlook: The company expects a significant improvement in the residential market in the second half of 2026 and 2027 due to a supply trough in multifamily housing. Multifamily construction starts are down 70% from their 2022 peak, locking in a multiyear supply trough. Demand remains strong as the cost to own a home is approximately three times the cost to rent.
Life Sciences Sector Outlook: The Alewife project is 71% leased, with strong leasing momentum and credit improvement. The demand for life science infrastructure is widening due to AI companies requiring similar facilities. The company expects continued improvement in the credit profile of its life science assets.
Self-Storage Sector Outlook: The self-storage sector is in a cyclical bottoming process, with supply remaining muted. Forecasted deliveries over the next several years could be as low as 1% of existing stock. The company expects supply discipline to persist and pricing power to return.
Pipeline and Deployment: The company has a pipeline of approximately $190 million across 11 active deals and an additional $275 million in structured product opportunities. The blended return profile of the pipeline is well in excess of the cost of capital, with modest increases in cash available for distribution expected throughout the back half of 2026.
AI Integration and Operational Efficiency: The company is deploying AI across underwriting, portfolio monitoring, credit risk, and operations functions. Full optimization is expected by 2027, leading to faster decisions, sharper risk management, and a scalable platform for growth.
Dividend for Q1 2026: $0.50 per share, covered 1.16x by cash available for distribution.
Dividend for Q2 2026: Declared at $0.50 per share, payable in the second quarter of 2026.
Share Buyback Program: The company continues to buy back stock opportunistically at a meaningful discount to book value (~$19 per share).
The earnings call presents mixed signals: financial performance is stable, with improved earnings and cash distribution, but high leverage and sector weakness pose risks. The Q&A reveals no major disruption in multifamily capital markets and unique positioning in Alewife, but management's unclear response about income details raises concerns. The share buyback at a discount is positive, but overall market uncertainty and high debt levels temper optimism. The stock price is likely to remain stable over the next two weeks.
Despite a decline in profitability and cash available for distribution, the company shows positive developments in net income and book value. The Q&A section highlights optimism in life sciences and multifamily sectors, with management providing clear responses. However, concerns about high interest rates, supply chain costs, and flat storage sector performance remain. The dividend and buyback plans offer some shareholder return but are not enough to outweigh the mixed financial health and sectoral challenges. Overall, the sentiment is balanced, leading to a neutral prediction.
The earnings call presented a mixed outlook. Despite a positive increase in net income and interest income, there are notable challenges such as supply pressures in residential markets, sluggish self-storage demand, and life science leasing uncertainties. The Q&A revealed some resilience in specific projects but highlighted broader sector risks. The dividend remains stable, but earnings and cash available for distribution have decreased. Given these mixed signals, the stock price is likely to remain stable, resulting in a neutral sentiment.
The earnings call presents a mixed picture: strong net income and interest income improvements, but guidance for earnings available for distribution has decreased. Regulatory and debt management risks are notable concerns. Despite a positive leasing momentum in life sciences, supply chain challenges persist. Dividends are maintained, but no share repurchases were announced. The Q&A section highlights management's lack of clarity on credit loss provisions. Overall, the sentiment is neutral with potential for slight positive movement if risks are managed effectively.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.